Clinical Trial Update: GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dose-finding, efficacy, and safety of tesaglitazar (AZ 242) in adults with Type 2 diabetes mellitus completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tesaglitazar (AZ 242) (tesaglitazar)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 2 | Status: COMPLETED